• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖患者非酒精性脂肪性肝病的发生和临床管理:文献综述。

Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: a literature review.

机构信息

Department of Endocrinology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), No. 3, South Wandao Road, Xingu Chong, Wanjiang District, Dongguan City, Guangdong Province, China, Phone: +86-13580915733.

Department of Endocrinology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan City, Guangdong Province, China.

出版信息

J Pediatr Endocrinol Metab. 2020 May 26;33(5):579-584. doi: 10.1515/jpem-2019-0595.

DOI:10.1515/jpem-2019-0595
PMID:32187014
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely correlated with insulin resistance. Currently, the methods for clinical management of NAFLD patients mainly include removing causes, changing lifestyle and dietary structure, drug therapy and weight-loss surgery. This paper summarizes the occurrence and clinical management of NAFLD in patients with obesity, with the aim of formulating scientific clinical interventions for these patients and thus preventing the occurrence of NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)是一种代谢应激诱导的肝损伤,与胰岛素抵抗密切相关。目前,NAFLD 患者的临床治疗方法主要包括去除病因、改变生活方式和饮食结构、药物治疗和减肥手术。本文总结了肥胖患者中 NAFLD 的发生和临床管理,旨在为这些患者制定科学的临床干预措施,从而预防 NAFLD 的发生。

相似文献

1
Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: a literature review.肥胖患者非酒精性脂肪性肝病的发生和临床管理:文献综述。
J Pediatr Endocrinol Metab. 2020 May 26;33(5):579-584. doi: 10.1515/jpem-2019-0595.
2
Evolution of NAFLD and Its Management.非酒精性脂肪性肝病及其管理的演变。
Nutr Clin Pract. 2020 Feb;35(1):72-84. doi: 10.1002/ncp.10449. Epub 2019 Dec 16.
3
The role of diet and nutrient composition in nonalcoholic Fatty liver disease.饮食和营养成分在非酒精性脂肪肝病中的作用。
J Acad Nutr Diet. 2012 Mar;112(3):401-9. doi: 10.1016/j.jada.2011.10.007. Epub 2012 Mar 1.
4
[Nonalcoholic Fatty Liver Disease and Weight Loss].[非酒精性脂肪性肝病与体重减轻]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Oct 30;40(5):597-602. doi: 10.3881/j.issn.1000-503X.10524.
5
Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity.十二指肠空肠旁路术可改善饮食诱导肥胖的肥胖症啮齿动物的非酒精性脂肪性肝病,而不依赖于体重减轻。
Am J Physiol Gastrointest Liver Physiol. 2020 Oct 1;319(4):G502-G511. doi: 10.1152/ajpgi.00357.2019. Epub 2020 Aug 19.
6
Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.肥胖成年人的非酒精性脂肪性肝病:临床特点与当前管理策略
Clin Obes. 2014 Oct;4(5):243-53. doi: 10.1111/cob.12068. Epub 2014 Jul 28.
7
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.非酒精性脂肪性肝病和糖尿病:第二部分:治疗。
Diabetes Metab J. 2019 Apr;43(2):127-143. doi: 10.4093/dmj.2019.0034.
8
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.减肥、饮食、运动和减重手术对非酒精性脂肪性肝病的影响。
Clin Liver Dis. 2016 May;20(2):339-50. doi: 10.1016/j.cld.2015.10.008. Epub 2016 Feb 17.
9
Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors.非酒精性脂肪性肝病及相关饮食和生活方式风险因素。
Diabetes Metab Syndr. 2018 Jul;12(4):569-575. doi: 10.1016/j.dsx.2018.03.016. Epub 2018 Mar 16.
10
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes.体重减轻干预措施与非酒精性脂肪性肝病:优化肝脏结局
Diabetes Obes Metab. 2022 Feb;24 Suppl 2:44-54. doi: 10.1111/dom.14569. Epub 2021 Oct 24.

引用本文的文献

1
The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes.E3 泛素连接酶 Trim31 通过靶向肝细胞中的 Rhbdf2 缓解非酒精性脂肪性肝病。
Nat Commun. 2022 Feb 25;13(1):1052. doi: 10.1038/s41467-022-28641-w.
2
A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix.用于非酒精性脂肪性肝病的候选药物:何首乌药理学活性研究综述。
Biomed Res Int. 2020 Apr 20;2020:5462063. doi: 10.1155/2020/5462063. eCollection 2020.